Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"). Trading is expected to commence on the CSE under the symbol "EYE" at the open of markets on March 12, 2026.

Inas Said, CEO of Rise commented, "Listing publicly represents an important milestone for Rise Nano Optics and provides the Company with a strong platform to accelerate growth and expand market awareness. With a robust intellectual property portfolio, FDA-registered optical technology and exposure to a global eyewear market valued in the hundreds of billions of dollars, Rise is well-positioned to execute on its commercialization strategy across North America and globally. Access to the public markets will support the scaling of our SPECTRAGUARD™ technology, the expansion of partnerships with optical labs and industry leaders and the continued development of innovative solutions designed to address the growing demand for advanced eye protection worldwide."

Transforming Preventative Vision Care

Rise is redefining the optical lens market with proprietary nanotechnology lens treatments that extend protection beyond traditional UV-only standards and into the 400-600nm high-energy visible light spectrum. A growing body of peer-reviewed research continues to examine the biological impact of high-energy visible wavelengths between 400-600nm, driving increased attention to advanced optical strategies.

Unlike conventional eyewear solutions that focus solely on non-visible UV light, Rise's technology filters up to 90% of the wavelengths between 400-600nm while enhancing contrast, preserving natural colour perception and reducing glare and stray light.

Addressing a Growing Global Medical Market

Rise is currently pursuing multiple product development pathways aimed at a significant and expanding medical and consumer market, driven by rising rates of diabetic retinopathy, macular degeneration, cataracts, photophobia and migraine-related light sensitivity, which collectively affect over one billion people worldwide.

With 92% of adults in the United States using some form of eyewear and the global eyewear market projected to grow from approximately US$161 billion in 2025 to US$267 billion by 2034, Rise is uniquely positioned at the intersection of preventative healthcare, optical innovation and consumer wellness.^[1]

Scalable Commercial Model and IP Leadership

The Company's global go-to-market strategy includes sales through existing third-party optical labs serving optometrists and other eyecare professionals, partnerships with established direct-to-consumer eyewear brands and selective optical lab acquisitions to accelerate adoption and revenue generation.

Rise's competitive moat is reinforced by a growing global intellectual property portfolio, including seven patents protecting its nano materials, production methods, application to pre-made lenses and finished lens architecture, providing multiple future product development pathways.

Strategic Outlook

Following FDA Class I exempt classification and completion of biocompatibility testing, Rise has completed its US product registration and is positioned to commence North American commercialization in Q1 2026, aligned with its public market debut.

About Rise

Rise Nano Optics Ltd. is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented SPECTRAGUARD™ technology integrates nanomaterial innovation, ophthalmic research, and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

For more information, visit: www.risenanooptics.com

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state of the United States in which such offer, solicitation or sale would be unlawful.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward‐Looking Statements

This news release contains forward-looking statements relating to the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the trading of the Common Shares and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations are risks detailed from time to time in the filings made by the Company with securities regulations.

Readers are cautioned that that forward-looking information is not based on historical facts but instead reflect the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the approval of the CSE to commence trading of the Common Shares, the demand for the Company's products and technology, including SPECTRAGUARD™, the expansion of the Company's business partnerships and the success of the Company's patents and intellectual property, whether future or current. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

^[1] https://www.gminsights.com/industry-analysis/eyewear-market

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288135